SciClone renews product promotion agreement with Sanofi in China

Posted: January 30th, 2013  |  Company/topic: Sanofi
Website: PBR - Contract Services News
US-based SciClone Pharmaceuticals has renewed an exclusive agreement with Sanofi to promote four products including Depakine, Stilnox, Tritace and Xatral in China.
Tags: , ,

SciClone Announces Product Promotion Agreement Renewal With Key Industry Partner Sanofi in China

Posted: January 30th, 2013  |  Company/topic: Sanofi
Website: Marketwire - Breaking News Releases (English Only)
FOSTER CITY, CA--(Marketwire - Jan 30, 2013) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has successfully negotiated renewals of its exclusive product promotion agreement…
Tags: , ,

Eisai and Novartis part ways

Posted: January 8th, 2013  |  Company/topic: Novartis
Website: Pharmafile
Novartis and Eisai have abandoned their co-promotion agreement for three of Novartis’ chronic obstructive pulmonary disease treatments. The move follows what the companies call ‘a review o…
Tags: , ,

Horizon Pharma, Inc. and Mallinckrodt Inc., the Pharmaceuticals Business of Covidien, Enter Into Co-Promotion Agreement for DUEXIS?? in the United States

Posted: June 18th, 2012  |  Company/topic: Covidien
Website: BioSpace.com Featured News
DEERFIELD, Ill., June 18, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP) and Mallinckrodt LLC the Pharmaceuticals business of Covidien (NYSE: COV), announced today that they have entered int…
Tags: , , , , ,
« Older Entries